Consistent with the findings in CML mice, Sphk1 expression levels in 32D-BA cells remained unchanged and unresponsive to TKI treatment (Fig. 3D, E). This evidence concerns the gene SPHK1 and chronic myelogenous leukemia, BCR-ABL1 positive.